 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 November 2004 | Volume 141 Issue 10 | Pages 781-788
In response to overwhelming evidence and the consequences of poor-quality reporting of randomized, controlled trials (RCTs), many medical journals and editorial groups have now endorsed the CONSORT (Consolidated Standards of Reporting Trials) statement, a 22-item checklist and flow diagram. Because CONSORT primarily aimed at improving the quality of reporting of efficacy, only 1 checklist item specifically addressed the reporting of safety.
Considerable evidence suggests that reporting of harms-related data from RCTs also needs improvement. Members of the CONSORT Group, including journal editors and scientists, met in Montebello, Quebec, Canada, in May 2003 to address this problem. The result is the following document: the standard CONSORT checklist with 10 new recommendations about reporting harms-related issues, accompanying explanation, and examples to highlight specific aspects of proper reporting.
We hope that this document, in conjunction with other CONSORT-related materials (http://www.consort-statement.org), will help authors improve their reporting of harms-related data from RCTs. Better reporting will help readers critically appraise and interpret trial results. Journals can support this goal by revising Instructions to Authors so that they refer authors to this document.
*For a list of members of the CONSORT Group, see Appendix 1.
Author and Article Information
From University of Ioannina School of Medicine and Biomedical Research Institute, Foundation for Research and Technology–Hellas, Ioannina, Greece; London School of Hygiene and Tropical Medicine, London, United Kingdom; The Nordic Cochrane Centre, Copenhagen, Denmark; U.S. Food and Drug Administration, Rockville, Maryland; Cancer Research UK/National Health Service Centre for Statistics in Medicine, Oxford, United Kingdom; Family Health International, Research Triangle Park, North Carolina; and Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
For definitions of terms, see Glossary.
Disclaimer: Dr. O'Neill is an employee of the U.S. Food and Drug Administration. The views expressed are those of the author and do not necessarily represent those of the U.S. Food and Drug Administration.
Grant Support: Abbott Laboratories, Children's Hospital of Eastern Ontario Research Institute, Health Canada, The Lancet, and Merck and Co., Inc. provided funding for the Montebello meeting. Dr. Altman is supported by Cancer Research UK.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: David Moher, PhD, Chalmers Research Group, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, Ontario K1H 8L1, Canada; e-mail, dmoher{at}uottawa.ca.
Current Author Addresses: Dr. Ioannidis: Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, and Biomedical Research Institute, Foundation for Research and Technology-Hellas, Ioannina 45110, Greece.
Mr. Evans: Medical Statistics Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.
Dr. Gøtzsche: The Nordic Cochrane Centre, Rigshospitalet, Department 7112, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Dr. O'Neill: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.
Dr. Altman: Cancer Research UK/NHS Centre for Statistics in Medicine, Old Road Campus, Old Road, Headington, Oxford OX3 7LF, United Kingdom.
Dr. Schultz: Family Health International, PO Box 13950, Research Triangle Park, NC 27709.
Dr. Moher: Chalmers Research Group, Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, Ontario K1H 8L1, Canada. IMPROVING PATIENT CARE
Improving Patient Care is a special section within Annals supported in part by the U.S. Department of Health and Human Services (HHS) Agency for Healthcare Research and Quality (AHRQ). The opinions expressed in this article are those of the authors and do not represent the position or endorsement of AHRQ or HHS.
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Y. Chowers, B. S. Gottesman, L. Leibovici, U. Pielmeier, S. Andreassen, and M. Paul Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review J. Antimicrob. Chemother., May 28, 2009; (2009) dkp191v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Gill, G. M. Anderson, H. D. Fischer, C. M. Bell, P. Li, S.-L. T. Normand, and P. A. Rochon Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors: A Population-Based Cohort Study Arch Intern Med, May 11, 2009; 169(9): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Albavera-Hernandez, J. M Rodriguez, and A. J Idrovo Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials Clinical Rehabilitation, May 1, 2009; 23(5): 394 - 407. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Thomas and C. J. Dore Statistical guidelines for contributors to Rheumatology Rheumatology, May 1, 2009; 48(5): 461 - 461. [Full Text] [PDF]
|
|
|
|
 |
|
 C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Murad, F. Coto-Yglesias, A. T. Wang, N. Sheidaee, R. J. Mullan, M. B. Elamin, P. J. Erwin, and V. M. Montori Drug-Induced Hypoglycemia: A Systematic Review J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 741 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zwarenstein, S. Treweek, J. J Gagnier, D. G Altman, S. Tunis, B. Haynes, A. D Oxman, D. Moher, and for the CONSORT and Pragmatic Trials in Healthcare Improving the reporting of pragmatic trials: an extension of the CONSORT statement BMJ, December 30, 2008; 337(nov11_2): a2390 - a2390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Shcherbatykh, A. Holbrook, L. Thabane, L. Dolovich, and COMPETE III investigators Methodologic Issues in Health Informatics Trials: The Complexities of Complex Interventions J. Am. Med. Inform. Assoc., September 1, 2008; 15(5): 575 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zaslawski Ethical Considerations for Acupuncture and Chinese Herbal Medicine Clinical Trials: A Cross-cultural Perspective Evid. Based Complement. Altern. Med., August 21, 2008; (2008) nen055v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cranney, H. A Weiler, S. O'Donnell, and L. Puil Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health Am. J. Clinical Nutrition, August 1, 2008; 88(2): 513S - 519S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vohra, B. C. Johnston, K. L. Laycock, W. K. Midodzi, I. Dhunnoo, E. Harris, and L. Baydala Safety and Tolerability of North American Ginseng Extract in the Treatment of Pediatric Upper Respiratory Tract Infection: A Phase II Randomized, Controlled Trial of 2 Dosing Schedules Pediatrics, August 1, 2008; 122(2): e402 - e410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H Guyatt, A. D Oxman, R. Kunz, G. E Vist, Y. Falck-Ytter, H. J Schunemann, and for the GRADE Working Group What is "quality of evidence" and why is it important to clinicians? BMJ, May 3, 2008; 336(7651): 995 - 998. [Full Text] [PDF]
|
|
|
|
 |
|
 G Bertsias, C Gordon, and D. Boumpas Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials Lupus, May 1, 2008; 17(5): 437 - 442. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Cook MD, F. Lauzier MD, M. G. Rocha MD, M. J. Sayles RN, and S. Finfer MD Serious adverse events in academic critical care research Can. Med. Assoc. J., April 22, 2008; 178(9): 1181 - 1184. [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Anderson, D. Juurlink, and A. S. Detsky Newly Approved Does Not Always Mean New and Improved JAMA, April 2, 2008; 299(13): 1598 - 1600. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Armstrong, E. Waters, L. Moore, E. Riggs, L. G. Cuervo, P. Lumbiganon, and P. Hawe Improving the reporting of public health intervention research: advancing TREND and CONSORT J. Public Health Med., March 1, 2008; 30(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Boutron, D. Moher, D. G. Altman, K. F. Schulz, P. Ravaud, and for the CONSORT Group Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration Ann Intern Med, February 19, 2008; 148(4): 295 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Boutron, D. Moher, D. G. Altman, K. F. Schulz, P. Ravaud, and for the CONSORT Group Methods and Processes of the CONSORT Group: Example of an Extension for Trials Assessing Nonpharmacologic Treatments Ann Intern Med, February 19, 2008; 148(4): W-60 - W-66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nieto, A. Mazon, R. Pamies, J. J. Linana, A. Lanuza, F. O. Jimenez, A. Medina-Hernandez, and F. J. Nieto Adverse Effects of Inhaled Corticosteroids in Funded and Nonfunded Studies Arch Intern Med, October 22, 2007; 167(19): 2047 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. v. Elm, D. G Altman, M. Egger, S. J Pocock, P. C Gotzsche, J. P Vandenbroucke, and STROBE Initiative Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies BMJ, October 20, 2007; 335(7624): 806 - 808. [Full Text] [PDF]
|
|
|
|
|
|
E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gotzsche, J. P. Vandenbroucke, and for the STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies Ann Intern Med, October 16, 2007; 147(8): 573 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chou and L. H. Huffman Nonpharmacologic Therapies for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline Ann Intern Med, October 2, 2007; 147(7): 492 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chou and L. H. Huffman Medications for Acute and Chronic Low Back Pain: A Review of the Evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline Ann Intern Med, October 2, 2007; 147(7): 505 - 514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tonelli, N. Wiebe, B. Culleton, H. Lee, S. Klarenbach, F. Shrive, B. Manns, and for the Alberta Kidney Disease Network Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2856 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ebrahim and M. Clarke STROBE: new standards for reporting observational epidemiology, a chance to improve Int. J. Epidemiol., October 1, 2007; 36(5): 946 - 948. [Full Text] [PDF]
|
|
|
|
|
|
S. N. Goodman Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials Ann Intern Med, June 19, 2007; 146(12): 882 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Zarin, N. C. Ide, T. Tse, W. R. Harlan, J. C. West, and D. A. B. Lindberg Issues in the Registration of Clinical Trials JAMA, May 16, 2007; 297(19): 2112 - 2120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Stone, B. S. Cooper, C. C. Kibbler, B. D. Cookson, J. A. Roberts, G. F. Medley, G. Duckworth, R. Lai, S. Ebrahim, E. M. Brown, et al. The ORION statement: guidelines for transparent reporting of Outbreak Reports and Intervention studies Of Nosocomial infection J. Antimicrob. Chemother., May 1, 2007; 59(5): 833 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perez-Gomez, J. A. Iriarte, J. Zumalde, J. Berjon, A. Salvador, E. Alegria, M. P. Maluenda, S. Asenjo, R. Perez-Saldana, R. G. de la Torre, et al. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial Eur. Heart J., April 2, 2007; 28(8): 996 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. A. Ioannidis, D. Mauri, N. P. Polyzos, and N. Pavlidis Response: Re: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis J Natl Cancer Inst, January 17, 2007; 99(2): 176 - 177. [Full Text] [PDF]
|
|
|
|
|
|
Y Yazici and H Yazici A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vohra, B. C. Johnston, K. Cramer, and K. Humphreys Adverse Events Associated With Pediatric Spinal Manipulation: A Systematic Review Pediatrics, January 1, 2007; 119(1): e275 - e283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marks, D. Ciliska, and A. Jull Evaluation of studies of treatment harm Evid. Based Nurs., October 1, 2006; 9(4): 100 - 104. [Full Text] [PDF]
|
|
|
|
|
|
J. K. Erban and J. Lau On the Toxicity of Chemotherapy for Breast Cancer--the Need for Vigilance. J Natl Cancer Inst, August 16, 2006; 98(16): 1096 - 1097. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Elbourne Book Review: Advances in clinical trial biostatistics Clinical Trials, August 1, 2006; 3(4): 408 - 409. [PDF]
|
|
|
|
 |
|
 V. M. Montori, Y. G. Wang, P. Alonso-Coello, and S. Bhagra Systematic Evaluation of the Quality of Randomized Controlled Trials in Diabetes Diabetes Care, August 1, 2006; 29(8): 1833 - 1838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.A. Ioannidis and P. Papanikolaou Not-so-surprising findings. Can. Med. Assoc. J., July 18, 2006; 175(2): 172 - 172. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schwartzman, Y. Yazici, W. D. Rifkin, and M. R. McClung Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med., June 1, 2006; 354(22): 2390 - 2391. [Full Text] [PDF]
|
|
|
|
|
|
O. M. Wazni, T. S. Fahmy, A. Natale, S. K. Aberegg, D. Majure, J. Auer, G. Lamm, B. Eber, H. Oral, C. Pappone, et al. Circumferential pulmonary-vein ablation for atrial fibrillation. N. Engl. J. Med., May 25, 2006; 354(21): 2289 - 2291. [Full Text] [PDF]
|
|
|
|
|
|
T. Kober, S. Trelle, and A. Engert Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. J Natl Cancer Inst, May 3, 2006; 98(9): 620 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Piaggio, D. R. Elbourne, D. G. Altman, S. J. Pocock, S. J. W. Evans, and for the CONSORT Group Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement JAMA, March 8, 2006; 295(10): 1152 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Papanikolaou, G. D. Christidi, and J. P.A. Ioannidis Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies Can. Med. Assoc. J., February 28, 2006; 174(5): 635 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bent, A. Padula, and A. L. Avins Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med, February 21, 2006; 144(4): 257 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.A. Ioannidis, C. D. Mulrow, and S. N. Goodman Adverse events: the more you search, the more you find. Ann Intern Med, February 21, 2006; 144(4): 298 - 300. [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Hull, G. F. Pineo, R. F. Brant, and for the LITE Trial Investigators Self-Managed Long-Term Low-Molecular-Weight Heparin Compared with Usual-Care Anticoagulation for Patients with Proximal Venous Thrombosis: Harm Associated with Bleeding!. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 901 - 901. [Abstract]
|
|
|
|
|
|
R. D. Hull, G. F. Pineo, R. F. Brant, and for the LITE Trial Investigators Self-Managed Long-Term Low-Molecular-Weight Heparin Therapy Compared with Usual-Care Anticoagulation for the Treatment of Patients with Proximal Venous Thrombosis: Harm Associated with Thrombocytopenia. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4142 - 4142. [Abstract]
|
|
|
|
 |
|
 S. Frank, K. Kieburtz, R. Holloway, and S. Y.H. Kim What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports Neurology, October 11, 2005; 65(7): 1101 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ethgen, I. Boutron, G. Baron, B. Giraudeau, J. Sibilia, and P. Ravaud Reporting of Harm in Randomized, Controlled Trials of Nonpharmacologic Treatment for Rheumatic Disease Ann Intern Med, July 5, 2005; 143(1): 20 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chou and M. Helfand Challenges in Systematic Reviews That Assess Treatment Harms Ann Intern Med, June 21, 2005; 142(12_Part_2): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Juni, S. Reichenbach, and M. Egger COX 2 inhibitors, traditional NSAIDs, and the heart BMJ, June 11, 2005; 330(7504): 1342 - 1343. [Full Text] [PDF]
|
|
|
|
|
|
E. Ernst Acupuncture for Chronic Mechanical Neck Pain Ann Intern Med, May 17, 2005; 142(10): 873 - 873. [Full Text] [PDF]
|
|
|
|
|
|
J. O. Friedrich, N. Adhikari, M. S. Herridge, and J. Beyene Meta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death Ann Intern Med, April 5, 2005; 142(7): 510 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-W. Chan and D. G Altman Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors BMJ, April 2, 2005; 330(7494): 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Soares, A. Kumar, S. Daniels, S. Swann, A. Cantor, I. Hozo, M. Clark, F. Serdarevic, C. Gwede, A. Trotti, et al. Evaluation of New Treatments in Radiation Oncology: Are They Better Than Standard Treatments? JAMA, February 23, 2005; 293(8): 970 - 978. [Abstract] [Full Text] [PDF]
|
|
